Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care. 2006;29:798–804.
Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA. 2015;313:37–44.
Rawshani A, Rawshani A, Franzen S, Eliasson B, Svensson AM, Miftaraj M, et al. Range of risk factor levels: control, mortality, and cardiovascular outcomes in type 1 diabetes mellitus. Circulation. 2017;135:1522–31.
Rawshani A, Rawshani A, Sattar N, Franzen S, McGuire DK, Eliasson B, et al. Relative prognostic importance and optimal levels of risk factors for mortality and cardiovascular outcomes in type 1 diabetes mellitus. Circulation. 2019;139:1900–12.
Bebu I, Keshavarzi S, Gao X, Braffett BH, Canty AJ, Herman WH, et al. Genetic risk factors for CVD in type 1 diabetes: the DCCT/EDIC study. Diabetes Care. 2021;44:1309–16.
Eliasson M, Jansson JH, Lundblad D, Naslund U. The disparity between long-term survival in patients with and without diabetes following a first myocardial infarction did not change between 1989 and 2006: an analysis of 6,776 patients in the Northern Sweden MONICA Study. Diabetologia. 2011;54:2538–43.
Ritsinger V, Nystrom T, Saleh N, Lagerqvist B, Norhammar A. Heart failure is a common complication after acute myocardial infarction in patients with diabetes: a nationwide study in the SWEDEHEART registry. Eur J Prev Cardiol. 2020;27:1890–901.
Smolina K, Wright FL, Rayner M, Goldacre MJ. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes. 2012;5:532–40.
Lowel H, Koenig W, Engel S, Hormann A, Keil U. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. Diabetologia. 2000;43:218–26.
Hoebers LP, Claessen BE, Woudstra P, DeVries JH, Wykrzykowska JJ, Vis MM, et al. Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin-treated diabetes mellitus. EuroIntervention. 2014;10:90–6.
Antoniucci D, Valenti R, Migliorini A, Parodi G, Moschi G, Memisha G, et al. Impact of insulin-requiring diabetes mellitus on effectiveness of reperfusion and outcome of patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2004;93:1170–2.
Kerola AM, Juonala M, Palomaki A, Semb AG, Rautava P, Kyto V. Case fatality of patients with type 1 diabetes after myocardial infarction. Diabetes Care. 2022;45:1657–65.
Kerola AM, Palomaki A, Rautava P, Nuotio M, Kyto V. Sex differences in cardiovascular outcomes of older adults after myocardial infarction. J Am Heart Assoc. 2021;10: e022883.
Kyto V, Nuotio M, Rautava P. Sex difference in the case fatality of older myocardial infarction patients. J Gerontol A Biol Sci Med Sci. 2022;77:614–20.
Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133:601–9.
VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the e-value. Ann Intern Med. 2017;167:268–74.
Matetic A, Doolub G, Bharadwaj A, Osman M, Biondi-Zoccai G, Ullah W, et al. Differential impact of type 1 and type 2 diabetes mellitus on outcomes among 1.4 million us patients undergoing percutaneous coronary intervention. Cardiovasc Revasc Med. 2022;38:83–8.
Tajik AA, Dobre D, Aguilar D, Kjekshus J, Zannad F, Dickstein K, et al. A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High-Risk MI Database. Eur J Heart Fail. 2017;19:635–42.
Svensson AM, Dellborg M, Abrahamsson P, Karlsson T, Herlitz J, Duval SJ, et al. The influence of a history of diabetes on treatment and outcome in acute myocardial infarction, during two time periods and in two different countries. Int J Cardiol. 2007;119:319–25.
Bundhun PK, Li N, Chen MH. Adverse cardiovascular outcomes between insulin-treated and non-insulin treated diabetic patients after percutaneous coronary intervention: a systematic review and meta-analysis. Cardiovasc Diabetol. 2015;14:135.
Biswas S, Dinh D, Andrianopoulos N, Lefkovits J, Ajani A, Duffy SJ, et al. Comparison of long-term outcomes after percutaneous coronary intervention in patients with insulin-treated versus non-insulin treated diabetes mellitus. Am J Cardiol. 2021;148:36–43.
Verges B. Cardiovascular disease in type 1 diabetes: a review of epidemiological data and underlying mechanisms. Diabetes Metab. 2020;46:442–9.
Matuleviciene-Anangen V, Rosengren A, Svensson AM, Pivodic A, Gudbjornsdottir S, Wedel H, et al. Glycaemic control and excess risk of major coronary events in persons with type 1 diabetes. Heart. 2017;103:1687–95.
Gubitosi-Klug R, Gao X, Pop-Busui R, de Boer IH, White N, Aiello LP, et al. Associations of microvascular complications with the risk of cardiovascular disease in type 1 diabetes. Diabetes Care. 2021;44:1499–505.
Parente EB, Harjutsalo V, Forsblom C, Groop PH, FinnDiane Study G. The impact of central obesity on the risk of hospitalization or death due to heart failure in type 1 diabetes: a 16-year cohort study. Cardiovasc Diabetol. 2021;20:153.
Lee AS, Twigg SM, Flack JR. Metabolic syndrome in type 1 diabetes and its association with diabetes complications. Diabet Med. 2021;38: e14376.
Wu N, Bredin SSD, Jamnik VK, Koehle MS, Guan Y, Shellington EM, et al. Association between physical activity level and cardiovascular risk factors in adolescents living with type 1 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol. 2021;20:62.
Bebu I, Schade D, Braffett B, Kosiborod M, Lopes-Virella M, Soliman EZ, et al. Risk factors for first and subsequent CVD events in type 1 diabetes: the DCCT/EDIC study. Diabetes Care. 2020;43:867–74.
Nystrom T, Holzmann MJ, Eliasson B, Kuhl J, Sartipy U. Glycemic control in type 1 diabetes and long-term risk of cardiovascular events or death after coronary artery bypass grafting. J Am Coll Cardiol. 2015;66:535–43.
Bernelli C, Chan J, Chieffo A. Drug-eluting stent outcomes in diabetes. Expert Rev Cardiovasc Ther. 2014;12:95–109.
Akin I, Bufe A, Eckardt L, Reinecke H, Senges J, Richardt G, et al. Comparison of outcomes in patients with insulin-dependent versus non-insulin dependent diabetes mellitus receiving drug-eluting stents (from the first phase of the prospective multicenter German DES.DE registry). Am J Cardiol. 2010;106:1201–7.
Pajunen P, Taskinen MR, Nieminen MS, Syvanne M. Angiographic severity and extent of coronary artery disease in patients with type 1 diabetes mellitus. Am J Cardiol. 2000;86:1080–5.
Ritsinger V, Hero C, Svensson AM, Saleh N, Lagerqvist B, Eeg-Olofsson K, et al. Mortality and extent of coronary artery disease in 2776 patients with type 1 diabetes undergoing coronary angiography: a nationwide study. Eur J Prev Cardiol. 2017;24:848–57.
Johansson I, Norhammar A. Diabetes and heart failure notions from epidemiology including patterns in low-, middle- and high-income countries. Diabetes Res Clin Pract. 2021;177: 108822.
Mamet H, Petrie MC, Rocchiccioli P. Type 1 diabetes mellitus and coronary revascularization. Cardiovasc Endocrinol Metab. 2019;8:35–8.
Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020;17:585–607.
Shah AS, Isom S, Dabelea D, D’Agostino R Jr, Dolan LM, Wagenknecht L, et al. A cross sectional study to compare cardiac structure and diastolic function in adolescents and young adults with youth-onset type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Study. Cardiovasc Diabetol. 2021;20:136.
Penna C, Andreadou I, Aragno M, Beauloye C, Bertrand L, Lazou A, et al. Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols. Br J Pharmacol. 2020;177:5312–35.
Sousa GR, Pober D, Galderisi A, Lv H, Yu L, Pereira AC, et al. Glycemic control, cardiac autoimmunity, and long-term risk of cardiovascular disease in type 1 diabetes mellitus. Circulation. 2019;139:730–43.
Gottumukkala RV, Lv H, Cornivelli L, Wagers AJ, Kwong RY, Bronson R, et al. Myocardial infarction triggers chronic cardiac autoimmunity in type 1 diabetes. Sci Transl Med. 2012. https://doi.org/10.1126/scitranslmed.3003551.
Chan SL, Edwards NJ, Conell C, Ren X, Banki NM, Rao VA, et al. Age, race/ethnicity, and comorbidities predict statin adherence after ischemic stroke or myocardial infarction. Eur J Prev Cardiol. 2020;27:2299–301.
Norhammar A, Malmberg K, Ryden L, Tornvall P, Stenestrand U, Wallentin L, et al. Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J. 2003;24:838–44.
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.
Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-Raiha P, Karja-Koskenkari P, et al. The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2005;12:132–7.
Vuori MA, Laukkanen JA, Pietila A, Havulinna AS, Kahonen M, Salomaa V, et al. The validity of heart failure diagnoses in the Finnish Hospital Discharge Register. Scand J Public Health. 2020;48:20–8.
Tolonen H, Salomaa V, Torppa J, Sivenius J, Immonen-Raiha P, Lehtonen A, et al. The validation of the Finnish Hospital Discharge Register and Causes of Death Register data on stroke diagnoses. Eur J Cardiovasc Prev Rehabil. 2007;14:380–5.